文献速递肝病

双膦酸盐在肝硬化患者中的有效性:一项模拟临床试验

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-26

该研究利用2008-2020年美国国家医保数据,采用新用药者设计模拟临床试验,比较肝硬化合并骨质疏松患者使用与未使用双膦酸盐的5年骨折风险。意向性分析显示双膦酸盐显著降低总体骨折(27.5% vs 33.0%,p=0.0004),但治疗依从性不一致,双膦酸盐使用者随访期间仅29.9%人年用药。

要点

  • 双膦酸盐显著降低肝硬化合并骨质疏松患者总体骨折风险(27.5% vs 33.0%,p=0.0004)。
  • 年龄<65岁、男性及非酒精性肝病患者中骨折风险降低更明显(sHR分别为0.56、0.64、0.85)。
  • 双膦酸盐使用者随访期间仅29.9%人年用药,治疗依从性不一致。

核心结论

  • 在具有全国代表性的老年肝硬化患者队列中,双膦酸盐总体上减少了骨折。
  • 需要采取措施提高双膦酸盐的 uptake 和药物续用。

研究设计与样本

  • 利用2008-2020年美国国家医保数据,采用新用药者设计模拟临床试验。
  • 纳入诊断为肝硬化合并骨质疏松的患者,比较接受与未接受双膦酸盐者的5年骨折风险。
  • 使用逆概率治疗加权平衡组间差异,评估意向性治疗和实际治疗效应,并检查对照暴露(他汀类使用)和对照结局(失代偿)以检验因果关系。

主要发现

  • 双膦酸盐新用药者253例,未用药者20,888例,中位年龄74岁。
  • 最常用双膦酸盐为阿仑膦酸钠(73.6%)。
  • 意向性分析中,双膦酸盐显著降低总体骨折(27.5% vs 33.0%,p=0.0004)。
  • 年龄<65岁者sHR 0.56,男性sHR 0.64,非酒精性肝病者sHR 0.85。
  • 臂部骨折(20.7% vs 26.4%,p<0.0001)和股骨骨折(28.9% vs 31.2%,p=0.005)减少,但脊柱骨折(25.8% vs 19.0%)、肋骨骨折(40.0% vs 32.2%)和颅骨骨折(10.1% vs 8.7%)增多。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Falls and fractures are common and morbid for patients with cirrhosis. Bisphosphonates are recommended for the prevention of fractures for people with osteoporosis cirrhosis; however, data supporting effectiveness in cirrhosis are lacking. AIM: We sought to emulate a clinical trial of bisphosphonates in cirrhosis. METHODS: We used national Medicare data (2008-2020) to examine the 5-year risk of fractures in patients who did or did not receive bisphosphonates with a new-user design among people diagnosed with cirrhosis and osteoporosis. We balanced treated and untreated with inverse probability of treatment weighting, evaluated intention-to-treat and as-treated effects, and examined both control exposures (statin use) and outcomes (decompensation) to test causal relationships. RESULTS: There were 253 and 20,888 new users and non-users of bisphosphonates, respectively. The median age was 74 years. The most common bisphosphonate used was alendronate (73.6%). Bisphosphonates significantly reduced fractures overall (27.5% vs. 33.0%, p = 0.0004) in the intention-to-treat analysis, particularly for people <65 years (sHR 0.56) old, men (sHR 0.64) and those with non-alcohol related liver disease (sHR 0.85). Though there were fewer arm (20.7% vs. 26.4%, p < 0.0001) and femur (28.9% vs. 31.2%, p = 0.005), there were more spinal (25.8% vs. 19.0%), rib (40.0% vs. 32.2%) and skull (10.1% vs. 8.7%) fractures. In the as-treated analysis, cumulative bisphosphonate exposure significantly reduced fractures, sHR 0.95 95% CI (0.91, 0.98). Treatment was inconsistent; bisphosphonate users spent 29.9% person-years of follow-up on the drug. CONCLUSION: In a nationally representative cohort of elderly patients with cirrhosis, bisphosphonates reduced fractures overall. Efforts to increase uptake and drug continuation are needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Martinez B, Jepsen P, et al. Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial. Aliment Pharmacol Ther. 2024. PMID: 38922994. doi:10.1111/apt.18127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。